Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD, Safety and Tolerability of SP2086 in Type 2 Diabetes
NCT02822534Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Apr 2016
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of retagliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration of SP2086 at Day 13, Steady-state Plasma Concentration of SP2086 at Day 13 and 6 more. Status: unknown.
02
Drugs
retagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02822534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02822534.